Search

Your search keyword '"Dehlendorff, Christian"' showing total 754 results
Start Over Author "Dehlendorff, Christian"
754 results on '"Dehlendorff, Christian"'

3. A randomized double-blind single center study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig cell insufficiency (Einstein-intervention)

Author

Kreiberg, Michael, Jørgensen, Niels, Juul, Anders, Lauritsen, Jakob, Oturai, Peter, Helge, Jørn Wulff, Christensen, Jesper Frank, Aksglaede, Lise, Schauer, Tim, Wagner, Thomas, Rosenvilde, Josephine, Grunwald, Emma, Dehlendorff, Christian, Daugaard, Gedske, and Bandak, Mikkel

Published
2022
Full Text
View/download PDF

12. In reply

Author

Uldbjerg, Cecilie S., Wilson, Louise F., Koch, Trine, Christensen, Jane, Dehlendorff, Christian, Priskorn, Lærke, Abildgaard, Julie, Simonsen, Mette K., Lim, Youn-Hee, Andersen, Zorana J., Juul, Anders, Hickey, Martha, and Bräuner, Elvira V.

Published
2022
Full Text
View/download PDF

14. Long-term exposure to road traffic noise and stroke incidence: a Danish Nurse Cohort study

Author

Cole-Hunter, Tom, Dehlendorff, Christian, Amini, Heresh, Mehta, Amar, Lim, Youn-Hee, Jørgensen, Jeanette T., Li, Shuo, So, Rina, Mortensen, Laust H., Westendorp, Rudi, Hoffmann, Barbara, Bräuner, Elvira V., Ketzel, Matthias, Hertel, Ole, Brandt, Jørgen, Jensen, Steen Solvang, Christensen, Jesper H., Geels, Camilla, Frohn, Lise M., Backalarz, Claus, Simonsen, Mette K., Loft, Steffen, and Andersen, Zorana J.

Published
2021
Full Text
View/download PDF

21. Long-term aspirin use and cancer risk: a 20-year cohort study.

Author

Skriver, Charlotte, Maltesen, Thomas, Dehlendorff, Christian, Skovlund, Charlotte Wessel, Schmidt, Morten, Sørensen, Henrik Toft, and Friis, Søren

Subjects
ASPIRIN, DISEASE risk factors, HEAD & neck cancer, COHORT analysis, NON-Hodgkin's lymphoma, BRAIN tumors
Abstract

Background Long-term use of aspirin has been shown to reduce colorectal cancer risk, but the association remains inconclusive for individual noncolorectal cancers. We examined the association between long-term aspirin use and cancer risk in Denmark. Methods Using nationwide registries, we followed individuals aged 40-70 years at baseline (January 1, 1997) for cancer diagnoses through 2018. We assessed low-dose (75-150 mg) aspirin use according to continuity, duration, and cumulative amount. In addition, we explored associations with consistent high-dose (500 mg) aspirin use. Using Cox regression, we estimated multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) with aspirin use for overall and site-specific cancer. Results Among 1 909 531 individuals, 422 778 were diagnosed with cancer during mean follow-up of 18.2 years. Low-dose aspirin use did not reduce the hazard ratio for cancer overall irrespective of continuity and duration of use (continuous use: HR = 1.04, 95% CI = 1.03 to 1.06). However, long-term (≥5 or ≥10 years) use was associated with at least 10% reductions in hazard ratios for several cancer sites: colon, rectum, esophagus, stomach, liver, pancreas, small intestine, head and neck, brain tumors, meningioma, melanoma, thyroid, non-Hodgkin lymphoma, and leukemia. Substantially elevated hazard ratios were found for lung and bladder cancer. In secondary analyses, consistent high-dose aspirin use was associated with reduced hazard ratios for cancer overall (HR = 0.89, 95% CI = 0.85 to 0.93) and for several cancer sites. Conclusion Long-term low-dose aspirin use was associated with slight to moderately reduced risks for several cancers but not for cancer overall owing to increased risk for some common cancers. Similar or slightly stronger inverse associations were observed for consistent use of high-dose aspirin. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Human papillomavirus vaccination and anal high-grade precancerous lesions and cancer—a real-world effectiveness study.

Author

Baandrup, Louise, Maltesen, Thomas, Dehlendorff, Christian, and Kjaer, Susanne K

Subjects
ANAL cancer, HUMAN papillomavirus vaccines, PRECANCEROUS conditions, VACCINE effectiveness, VACCINATION status, HUMAN papillomavirus
Abstract

Background Human papillomavirus (HPV) vaccination has shown high efficacy against anal HPV infection and lesions in clinical trials, and the HPV prevalence and type distribution in anal precancers and cancer predict a high preventable potential for HPV vaccination. However, the real-world effectiveness of HPV vaccination against anal high-grade lesions and cancer is yet to be shown. Methods We investigated HPV vaccine effectiveness against anal high-grade squamous intraepithelial lesion (HSIL) or worse in a nationwide cohort including all Danish women aged 17-32 years during October 2006 to December 2021 (n = 968 881). HPV vaccinations and first occurrence of anal HSIL or worse were retrieved from nationwide registries. Women were considered vaccinated after first dose and classified by age at vaccination. Using Cox regression, hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for anal HSIL or worse according to vaccination status. Results During follow-up, the number of incident histological anal HSIL or worse cases was 37 in unvaccinated women, and less than 5 and 26 in women vaccinated at ages younger than 17 years and 17-32 years, respectively. The overall number of cancers was less than 5. Compared with unvaccinated women, the risk of histological anal HSIL or worse was reduced for women vaccinated at age younger than 17 years (HR = 0.30, 95% CI = 0.10 to 0.87). For women vaccinated at age 17-32 years, the hazard rate of anal HSIL or worse was 1.21 (95% CI = 0.73 to 2.03). Conclusion This is the first study to demonstrate that HPV vaccination at a younger age is associated with substantially reduced risk of anal HSIL or worse in the general population. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Long-Term Exposure to Road Traffic Noise and Air Pollution, and Incident Atrial Fibrillation in the Danish Nurse Cohort

Author

Andersen, Zorana J., Cramer, Johannah, Jorgensen, Jeanette T., Dehlendorff, Christian, Amini, Heresh, Mehta, Amar, Cole-Hunter, Tom, Mortensen, Laust H., Westendorp, Rudi, So, Rina, Li, Shuo, Hoffmann, Barbara, Loft, Steffen, Brauner, Elvira V., Ketzel, Matthias, Hertel, Ole, Brandt, Jorgen, Jensen, Steen Solvang, Christensen, Jesper H., Geels, Camilla, Frohn, Lise M., Backalarz, Claus, Simonsen, Mette K., and Lim, Youn-Hee

Subjects
Traffic noise -- Health aspects, Atrial fibrillation -- Risk factors -- Environmental aspects, Air pollution -- Health aspects, Environmental issues, Health
Abstract

Background: Associations between long-term exposure to air pollution and road traffic noise have been established for ischemic heart disease, but findings have been mixed for atrial fibrillation (AF). Objectives: The goal of the study was to examine associations of long-term exposure to road traffic noise and air pollution with AF. Methods: Time-varying Cox regression models were used to estimate associations of 1-, 3-, and 23-y mean road traffic noise and air pollution exposures with AF incidence in 23,528 women enrolled in the Danish Nurse Cohort (age >44 y at baseline in 1993 or 1999). AF diagnoses were ascertained via the Danish National Patient Register. Annual mean weighted 24-h average road traffic noise levels ([L.sub.den]) at the nurses' residences, since 1970, were estimated using the Nord2000 model, and annual mean levels of particulate matter with a diameter Results: Of 23,528 nurses with no prior AF diagnosis at the cohort baseline, 1,522 developed AF during follow-up. In a fully adjusted model (including [PM.sub.2.5]), the estimated risk of AF was 18% higher [hazard ratio (HR); 95% confidence interval (CI): 1.18; 1.02, 1.36] in nurses with residential 3-y mean [L.sub.den] levels >58dB vs. Conclusion: Our analysis of prospective data from a cohort of Danish female nurses followed for up to 14 y provided suggestive evidence of independent associations between incident AF and 1- and 3-y exposures to road traffic noise and [PM.sub.2.5]. https://doi.org/10.1289/EHP8090, Introduction Atrial fibrillation (AF) is the most common type of cardiac arrhythmia, characterized by abnormal electrophysiology of the heart's atria (Kirchhof et al. 2016). AF increases the risk of stroke, [...]

Published
2021
Full Text
View/download PDF

31. Development and external validation of nomograms in oropharyngeal cancer patients with known HPV-DNA status: a European Multicentre Study (OroGrams)

Author

Grønhøj, Christian, Jensen, David H., Dehlendorff, Christian, Marklund, Linda, Wagner, Steffen, Mehanna, Hisham, Munck-Wikland, Eva, Ramqvist, Torbjörn, Näsman, Anders, Wittekindt, Claus, Würdemann, Nora, Sharma, Shachi Jenny, Gattenlöhner, Stefan, Kiss, Katalin, Andersen, Elo, Spruce, Rachel, Batis, Nikos, Robinson, Max, Harrington, Kevin, Winter, Stuart, Jones, Terence M., Klussmann, Jens Peter, Dalianis, Tina, Friborg, Jeppe, and von Buchwald, Christian

Published
2018
Full Text
View/download PDF

34. Supplementary Figure 5 from Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers

Author

Høgdall, Dan, primary, O'Rourke, Colm J., primary, Dehlendorff, Christian, primary, Larsen, Ole F., primary, Jensen, Lars H., primary, Johansen, Astrid Z., primary, Dang, Hien, primary, Factor, Valentina M., primary, Grunnet, Mie, primary, Mau-Sørensen, Morten, primary, Oliveira, Douglas V.N.P., primary, Linnemann, Dorte, primary, Boisen, Mogens K., primary, Wang, Xin W., primary, Johansen, Julia S., primary, and Andersen, Jesper B., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figure 1 from Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers

Author

Høgdall, Dan, primary, O'Rourke, Colm J., primary, Dehlendorff, Christian, primary, Larsen, Ole F., primary, Jensen, Lars H., primary, Johansen, Astrid Z., primary, Dang, Hien, primary, Factor, Valentina M., primary, Grunnet, Mie, primary, Mau-Sørensen, Morten, primary, Oliveira, Douglas V.N.P., primary, Linnemann, Dorte, primary, Boisen, Mogens K., primary, Wang, Xin W., primary, Johansen, Julia S., primary, and Andersen, Jesper B., primary

Published
2023
Full Text
View/download PDF

36. Are education and cohabitation associated with health-related quality of life and self-management during breast cancer follow-up? A longitudinal study

Author

Karlsen, Randi V., Høeg, Beverley Lim, Dalton, Susanne Oksbjerg, Saltbæk, Lena, Dehlendorff, Christian, Johansen, Christoffer, Svendsen, Mads Nordahl, Bidstrup, Pernille E., Karlsen, Randi V., Høeg, Beverley Lim, Dalton, Susanne Oksbjerg, Saltbæk, Lena, Dehlendorff, Christian, Johansen, Christoffer, Svendsen, Mads Nordahl, and Bidstrup, Pernille E.

Abstract

Background: Oncologist-led follow-up after breast cancer (BC) is increasingly replaced with less intensive follow-up based on higher self-management, which may overburden the less resourceful patients. We examined whether socioeconomic factors measured recently after the implementation of a new follow-up program for BC patients were associated with health-related quality of life (HRQoL) and self-management 12 months later. Methodology: Between January and August 2017, we invited 1773 patients in Region Zealand, Denmark, to participate in baseline and 12 months follow-up questionnaires. The patients had surgery for low- and intermediate risk BC 1–10 years prior to the survey, and they had recently been allocated to the new follow-up program of either patient-initiated follow-up, or in-person or telephone follow-up with a nurse, based on patients’ preferences. We examined associations between socioeconomic factors (education and cohabitation) at baseline and two outcomes: HRQoL (EORTC QLQ-C30 and QLQ-BR23) and self-management factors (health care provider, confidence in follow-up, contact at symptoms of concern, and self-efficacy) at 12 months follow-up. Sensitivity analyses were performed according to time since diagnosis (≤ 5 > 5 years). Furthermore, we investigated whether treatment and self-management factors modified the associations. Results: A total of 987 patients were included in the analyses. We found no statistically significant associations between socioeconomic factors and HRQoL, except in patients ≤ 5 years from diagnosis. For self-management patients with short education were more likely to report that they had not experience relevant symptoms of concern compared to those with medium/long education (OR 1.75 95% CI: 1.04; 2.95). We found no clear patterns indicating that treatment or self-management factors modified the associations between socioeconomics’ and HRQoL. Conclusion: Overall socioeconomic factors did not influence HRQoL and self-managem

Published
2023

40. Hormonal contraception use before and after breast cancer diagnosis: A nationwide drug utilization study

Author

Mørch, Lina Steinrud, Friis, Søren, Meaidi, Amani, Dehlendorff, Christian, Skovlund, Charlotte Wessel, and Duun-Henriksen, Anne Katrine

Subjects
Contraceptives, Oral, Hormonal/adverse effects, Male, Epidemiology, Breast Neoplasms/diagnosis, Humans, Breast Neoplasms, Female, Pharmacology (medical), Hormonal Contraception, Drug Utilization, Contraceptives, Oral, Hormonal
Abstract

PURPOSE: To describe the use of hormonal contraceptives in Danish breast cancer patients.METHODS: Nationwide drug utilization study in Danish women diagnosed with breast cancer at ages 13-50 years during 2000-2015. User proportions were estimated in 6-months intervals from 2 years before to 2 years after diagnosis.RESULTS: Use of hormonal contraceptives declined sharply after breast cancer diagnosis. Still, 7% of patients aged 13-39 years filled hormonal contraceptive prescriptions within 6 months after the diagnosis.CONCLUSIONS: The majority of premenopausal breast cancer patients discontinues hormonal contraception at diagnosis. All prescribers of hormonal contraceptives should acknowledge that hormonal contraception is contraindicated for breast cancer patients.PLAIN LANGUAGE SUMMARY: Use of hormonal contraception is contraindicated among women with breast cancer. In this nationwide study, we assessed the use of hormonal contraceptives among all Danish premenopausal women diagnosed with breast cancer during 2000-2015. Hormonal contraceptive use was assessed within 2 years before and 2 years after breast cancer diagnosis. The majority of patients discontinued hormonal contraception at breast cancer diagnosis. However, 7% of patients aged 13-39 years filled hormonal contraceptive prescriptions within 6 months after the diagnosis.

Published
2022

49. Increased mortality in patients with hematologic malignancies treated with proton pump inhibitors: a nationwide cohort study.

Author

Vilmar, Adam, Dehlendorff, Christian, Friis, Søren, Jäättelä, Marja, Tvingsholm, Siri, and Frederiksen, Henrik

Subjects
*PROTON pump inhibitors, *HEMATOLOGIC malignancies, *COHORT analysis, *CANCER-related mortality, *CANCER patients
Abstract

Proton Pump inhibitors (PPIs) are frequently prescribed to cancer patients to prevent gastric mucosal damage. Post-diagnostic PPI use in patients with solid tumors may be associated with increased cancer mortality. However, the hazardous impact of PPIs in patients with hematologic malignancies remains unknown. This association was investigated in a large, retrospective cohort study using data from the Danish nationwide health registries. The outcomes were cancer-specific or non-cancer deaths. We identified 15,320 patients with hematologic malignancies and of these 1811 were identified as post-diagnostic PPI users. PPI users had significantly increased HRs for cancer-specific mortality (HR 1.31; 95% CI, 1.18–1.44) and 1-year cancer-specific mortality (HR 1.50, 95% CI 1.29–1.74) as compared to nonusers. The association between PPI use and increased cancer-specific mortality in Danish patients with hematologic malignancies supports the raised concerns regarding the frequent use of PPIs in cancer patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results